Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11264084 | 0.81 | ATM (0.43) | PARP10CTNNB1TDP1L3MBTL1TSHR | |
| SCHEMBL8941695 | 0.80 | ALDH1A1 (0.42) | PARP10CTNNB1KMT2AMEN1TDP1 | |
| SCHEMBL27672356 | 0.78 | PARP10 (0.42) | PARP10CTNNB1KMT2AMEN1TDP1 | |
| SCHEMBL3826087 | 0.77 | TDP1 (0.46) | PARP10CTNNB1KMT2AMEN1TDP1 | |
| SCHEMBL712279 | 0.76 | NPSR1 (0.54) | PARP10KMT2AMEN1TDP1L3MBTL1 | |
| SCHEMBL27343822 | 0.75 | PARP10 (0.40) | PARP10CTNNB1KMT2AMEN1TDP1 | |
| Hydrochloric Acid SCHEMBL30821401 | 0.74 | NPSR1 (0.52) | PARP10KMT2AMEN1TDP1L3MBTL1 | |
| SCHEMBL6236145 | 0.74 | L3MBTL1 (0.41) | PARP10L3MBTL1MAPTTSHRHSD17B10 | |
| Diphenylether SCHEMBL27544508 | 0.73 | PARP10 (0.61) | PARP10CTNNB1KMT2ATSHRALOX5 | |
| SCHEMBL11222117 | 0.72 | PARP10 (0.38) | PARP10CTNNB1KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824668-A | The polymorphic forms and pseudopolymorphic forms of medical compounds | 辉瑞爱尔兰制药公司 | 2019-05-31 | — | — | CN | disclosed |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD (BM) | 2017-07-27 | — | — | US | disclosed |
| US-9580424-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2017-02-28 | — | — | US | disclosed |
| CN-102834395-B | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | 阿斯利康控股法国有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20150246920-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-09-03 | — | — | US | disclosed |
| US-9062053-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-06-23 | — | — | US | disclosed |
| CN-104592229-A | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | ASTRA ZENECA HOLDING FRANCE SAS | 2015-05-06 | — | — | CN | disclosed |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2014-11-27 | — | — | US | disclosed |
| US-8835455-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2014-09-16 | — | — | US | disclosed |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8471025-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-06-25 | — | — | US | disclosed |
| CN-102834395-A | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | NOVEXEL SA | 2012-12-19 | — | — | CN | disclosed |
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885CTNNB1 2263/4885KMT2A 1843/4885 |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885CTNNB1 2263/4885KMT2A 1843/4885 |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885CTNNB1 2263/4885KMT2A 1843/4885 |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885CTNNB1 2263/4885KMT2A 1843/4885 |
| US-20150246920-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | PARP10 4527/4885CTNNB1 2263/4885KMT2A 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.